Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use

Following the clinical approval of TQB2930 for class 1 new drug injection, another class 1 new drug of Chia Tai Tianqing, TQH2722 injection, was approved for clinical use
.
Since 2022, Chia Tai Tianqing has 7 new Class 1 drugs approved for clinical use
.
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis
.
Atopic dermatitis is a common chronic, relapsing, inflammatory skin disease with a highly heterogeneous and protracted course
.
At present, there are not many domestic pharmaceutical companies that deploy Class 1 biological drugs for atopic dermatitis indications
.
On April 20, Sino Biopharmaceutical announced that TQB2930, a class 1 new anti-tumor drug for injection, was approved for clinical trials for the treatment of patients with advanced malignant tumors
.
TQB2930 is a bispecific antibody targeting solid tumor cells, achieving synergistic effects against both targets
.
Since the beginning of this year, Chia Tai Tianqing has obtained 7 Class 1 new drugs for clinical approval
.
Among them, 5 new drugs including TQH2722 injection, TQB2930 for injection, TQB3915 tablets, TQH3910 tablets, and TQH3821 tablets were approved for clinical use for the first time
.
TQB2618 injection is in phase I clinical stage, and TQB2450 injection (PD-L1 monoclonal antibody) is in phase III clinical stage
.
From 2022 to now, Chia Tai Tianqing has been approved for clinical use of Category 1 new drugs.
Data sources: Minet database, CDE